Banner for leaf pages 2

Eltrombopag (Promacta)

Also known as Promacta

Eltrombopag (rINN, codenamed SB-497115-GR) is a medication that has been developed for conditions that lead to thrombocytopenia (abnormally low platelet counts). It is a small molecule agonist of the c-mpl (TpoR) receptor, which is the physiological target of the hormone thrombopoietin. Eltrombopag was discovered as a result of research collaboration between GlaxoSmithKline and Ligand Pharmaceuticals. Designated an orphan drug in the USA and European Union, it is being manufactured and marketed by GlaxoSmithKline under the trade name Promacta in the USA and will be marketed as Revolade in the EU. Eltrombopag was approved by the U.S. Food and Drug Administration on November 20, 2008.

Source: Wikipedia

Estimated Total Cost: $3496.49 for an average of 28 days supply

What is it prescribed for?

Patients are most commonly prescribed eltrombopag to treat blastomycosis, rabies, west nile virus, and pick disease.

What drug interactions are known?

Do not take eltrombopag if you are taking any of the following:

Critical Interactions


Significant Interactions

Ajax-loader Loading...